The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the extracellular antigen-targeting CARs and the intracellular signaling modalities of CARs has not been system...

Descripción completa

Detalles Bibliográficos
Autores principales: Muller, Yannick D., Nguyen, Duy P., Ferreira, Leonardo M. R., Ho, Patrick, Raffin, Caroline, Valencia, Roxxana Valeria Beltran, Congrave-Wilson, Zion, Roth, Theodore L., Eyquem, Justin, Van Gool, Frederic, Marson, Alexander, Perez, Laurent, Wells, James A., Bluestone, Jeffrey A., Tang, Qizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021955/
https://www.ncbi.nlm.nih.gov/pubmed/33833759
http://dx.doi.org/10.3389/fimmu.2021.639818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021955/
https://www.ncbi.nlm.nih.gov/pubmed/33833759
http://dx.doi.org/10.3389/fimmu.2021.639818

Ejemplares similares